Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Characterization of DNA binding and transcriptional activity of disease-causing CRX mutants
Author Affiliations & Notes
  • Barry E Knox
    Ophthalmology & Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, United States
  • Cory A Knox
    Ophthalmology & Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, United States
  • Sarah E Reks
    Ophthalmology & Visual Sciences, SUNY Upstate Medical University, Syracuse, New York, United States
  • Footnotes
    Commercial Relationships   Barry Knox None; Cory Knox None; Sarah Reks None
  • Footnotes
    Support  Research to Prevent Blindness Unrestricted Grant to Department of Ophthalmology, Hoepner Family Fund (Upstate Medical University)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4705. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Barry E Knox, Cory A Knox, Sarah E Reks; Characterization of DNA binding and transcriptional activity of disease-causing CRX mutants. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4705.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The retina-specific transcription factor, CRX, regulates photoreceptor gene expression and development. Mutations in the homeodomain lead to retinal degeneration. Here, we compared the binding kinetics of several CRX homeodomain mutants using biolayer interferometry (BLI) with their transcriptional activation.

Methods : Human CRX homeodomain and mutants R41Q and R90W were expressed and purified in E. coli . BLI was used to measure protein-DNA interactions to DNA attached to sensor tips. Mutants were also prepared in full-length human CRX plasmids (pcDNA3.1) for assays in HEK293T cell transfections using PEI. Both the RHO and GNAT1 promoters were cloned into the pGL4 (Promega). Activity was measured using the Nano-Glo Dual-Luciferase Reporter Assay (Promega). Data was fit to saturable binding equations with 95% confidence intervals. Statistical comparisons were evaluated using two-way ANOVA (α = 0.05, n=3-4 for BLI and n=16-24 for transfections).

Results : The kinetics of CRXHD binding to short DNA cis-regulatory sequences from the rhodopsin promoter (BAT1) bound rapidly with biphasic kinetics and dissociated quickly also with biphasic kinetics. Both R41Q and R90W had reduced binding to DNA. R41Q exhibited a single binding site with ~20-fold reduction in steady state apparent binding constant-both on and off rates were altered. R90W showed less severe effects on binding (~5-10-fold reduction in steady state) with a two-state model, both on and off rates were altered. Transfection activity showed that R41Q mutation had 2-4 fold reduced activation activity both by itself and in combination with NRL. By contrast, the CRX-R90W mutant had basal levels of activity by itself or in combination with NRL at all concentrations of mutant DNA transfected.

Conclusions : These experiments show that while R41Q and R90W can bind to DNA, the R90W mutation renders the protein unable to activate transcription, suggesting a specific conformation(s) or orientation(s) of the homeodomain on cis-regulatory elements is essential for activating transcription. These results also indicate that such conformations could contribute to differential effects of disease-causing mutations in patients.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×